ALLR

Allarity Therapeutics, Inc. [ALLR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALLR Stock Summary

Top 10 Correlated Stocks

ALLR

In the News

ALLR Financial details

Company Rating
-
Market Cap
989.47K
Income
-12.8M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
-0.09
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.36
P/C
-
P/FCF
-0.22
Quick Ratio
0.19
Current Ratio
0.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-175.23
EPS next Y
-
EPS next Q
-
EPS this Y
-94.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.77%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-61.16%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-100%
ROE
2181%
ROC
10.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-13%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.01-3088.0
52W High
-99.97%
52W Low
-55.62%
RSI
44
Rel Volume
11.96
Avg Volume
59.62K
Volume
713.01K
Perf Week
-20.04%
Perf Month
-5.57%
Perf Quarter
-39.62%
Perf Half Y
-59.65%
-
-
-
-
Beta
0.242
-
-
Volatility
0.08%, 0.11%
Prev Close
-5.26%
Price
0.8876
Change
-12.98%

Something similar

Top by Market Cap
AMZN
TSLA
META
CMC.DE
BRK-B
Same Sector
TLRY.TO
CLNN
AVIR
SMSLIFE.NS
MODV
Top Correlated Stocks
HSII
1980.HK
Similar Market Cap
MAST.L
BRDS
INSP.L
OWN.V
EISB.L

Company Profile

Healthcare Biotechnology
  • Volume Average 59.62K
  • Market Capitalization 989.47K
  • Employee 5
  • CEO Mr. Thomas H. Jensen
  • Headquarters Cambridge,MA,US
  • IPO Date 2021-12-21
  • Website https://www.allarity.com

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.